02 Nov 2026, 17:02 IST
Zydus Lifesciences Limited
ICICI Securities Ltd. (Retail Equity Research) / ICICI Direct · BUY · target ₹1,480
The report assigns a BUY rating with a target of ₹1,480 (28x FY28E EPS), citing niche launches and the Rare and Orphan disease segment as growth drivers.
From idirect muhuratpick 2026, written by ICICI Securities Ltd. (Retail Equity Research) / ICICI Direct and hosted by ICICI Direct. Orivam summarised it; the view is ICICI Securities Ltd. (Retail Equity Research) / ICICI Direct's, not Orivam's.
Open the original PDF on ICICI Direct →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.